Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS INC. director Chris A. Rallis reported an option exercise combined with a related share sale. He exercised stock options covering 14,344 Common Shares at $2.44 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025. To cover tax obligations from this exercise, 8,346 Common Shares were sold at an average price of $7.04 per share. After these transactions, Rallis directly holds 63,077 Common Shares, reflecting a net increase in his equity position from the option exercise.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported an options-related share transaction in FENC. He exercised stock options to acquire 15,598 common shares at $2.45 per share and also received 2,778 previously restricted shares. On the same day, he sold 10,781 common shares in an open-market sale at $6.47 per share to satisfy tax obligations related to the option exercise, all under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. Following these transactions, Raykov directly holds 121,451 common shares.
FENC insider sale notice: A Form 144 was filed reporting a proposed sale of 10,781 shares of Common Stock via a stock option exercise on 05/01/2026. The filing lists prior cash sales by Rostislav Raykov of 10,946, 10,079 and 10,349 shares on 04/01/2026, 03/02/2026 and 02/02/2026 respectively, with the reported cash amounts shown in the record.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans acquired 168 Common Shares through an exercise or conversion of a derivative security at a stated price of $0.00 per share. A footnote explains these represent shares released from restriction from shares awarded on 3/28/2025. Following this transaction, Evans directly holds 20,847 Common Shares.
Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion. On April 30, 2026, 155 common shares were released from restriction from shares awarded on March 28, 2025, increasing her directly held stake.
Following this release, Cioffi directly owns 24,020 common shares. The transaction reflects routine equity-based compensation vesting rather than an open-market purchase, as the reported price per share was $0.0000.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.
After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade acquired 1,703 common shares on April 30, 2026 through an exercise or conversion of a derivative security reported at $0.00 per share.
After this transaction, Andrade directly owns 287,566 common shares. A footnote explains these shares were released from restriction from awards originally granted on May 16, 2024 and March 28, 2025.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on April 30, 2026 through the release of restricted shares that were originally awarded on March 28, 2025. After this compensation-related share release, he directly owns a total of 20,847 Common Shares.
Fennec Pharmaceuticals Inc. reported a planned change to its Board of Directors. On April 27, 2026, director Rostislav Raykov notified the company that he plans to retire from the Board and will not stand for re-election at the 2026 annual meeting of shareholders.
His current term will end immediately after the annual meeting, and his departure is stated to be not due to any disagreement with the company’s operations, policies, or practices. Before the meeting, the Board decided to reduce its size from six to five directors, effective immediately following the annual meeting, and the company expects no Board vacancies after the change.